Continuous Fascia Iliaca Compartment Block in Geriatric Hip Fracture

Sponsor
Mahidol University (Other)
Overall Status
Completed
CT.gov ID
NCT04914988
Collaborator
(none)
20
1
12.5
1.6

Study Details

Study Description

Brief Summary

The patient with hip fracture who has Numerical Rating Scale (NRS) ≥ 5 at rest or on movement will be indicated for USG FICB at Emergency Department or patient's ward.

The aim of this prospective observation study was evaluated the efficacy and complications of cFICB in adult hip fracture preoperatively.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The Enhance Recovery Program of pain management in geriatric hip fracture has been set up as a part of fast track at Siriraj Hospital since September 2017. The ultrasound-guided (USG) fascia iliaca compartment block (FICB) is routinely offered to patients with a hip fracture by acute pain service (APS) anesthesiologist. The patient with hip fracture who has Numerical Rating Scale (NRS) ≥ 5 at rest or on movement will be indicated for USG FICB.

    The aim of this prospective observation study was evaluated the efficacy and complications of cFICB in adult hip fracture preoperatively.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    20 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Pain Management in Geriatric Hip Fracture Patients With Ultrasound-guided Continuous Fascia Iliaca Compartment Block
    Actual Study Start Date :
    Feb 1, 2018
    Actual Primary Completion Date :
    Jan 30, 2019
    Actual Study Completion Date :
    Feb 15, 2019

    Outcome Measures

    Primary Outcome Measures

    1. numerical rating scale at rest [Change from baseline numerical rating scale at 30 minutes post-block]

      numerical rating scale 0-10 (0=no pain, 10=worst pain)

    2. numerical rating scale during movement [Change from baseline numerical rating scale at 30 minutes post-block]

      numerical rating scale 0-10 (0=no pain, 10=worst pain)

    Secondary Outcome Measures

    1. Numerical rating scale during movement [Within 48 hours postoperative]

      numerical rating scale 0-10 (0=no pain, 10=worst pain)

    2. Rate of complications of continuous fascia iliaca compartment analgesia [Within 48 hours postoperative]

      local anesthetic systemic toxicity, leakage, infection

    3. Duration of hospital admission [from hospital admission until hospital discharge, an average of 1 week]

      number of days

    4. Number of participants with morbidity and mortality [6 weeks after hospital discharge]

      myocardial disease, deep vein thrombosis, delirium, death

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    65 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patient age equal or more than 65 years old

    • patient with acute hip fracture within 7 days

    • patient with NRS ≥ 5

    Exclusion Criteria:
    • patient refusal

    • history of local anesthetic allergy

    • inability to communicate or cognitive dysfunction

    • multiple fracture involvement

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand 10700

    Sponsors and Collaborators

    • Mahidol University

    Investigators

    • Principal Investigator: Suwimon Tangwiwat, MD, Mahidol University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Suwimon Tangwiwat, Department of Anesthesiology, Mahidol University
    ClinicalTrials.gov Identifier:
    NCT04914988
    Other Study ID Numbers:
    • Si 113/2018
    First Posted:
    Jun 7, 2021
    Last Update Posted:
    Jun 7, 2021
    Last Verified:
    Jun 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 7, 2021